DOT1L and cancer: High-quality inhibitors have been developed for other histone methyltransferases, including DOT1L, PRMT5, G9a, GLP, SMYD2, SMYD3, SETD7, SUV420H1/2, and PRDM9.651 These inhibitors enable convenient evaluation of cancer cell dependency on the methyltransferases in different contexts and exploration of potential clinical use.